(Reuters) - Pfizer Inc(PFE.N)on Thursday reported a 78% jump in profit and reaffirmed the combined 2022 sales forecast of $54 billion for its COVID-19 vaccine and pill, as countries rushed to sign contracts to prepare for a surge of cases in the fall season.
Shares rose 1.3% in premarket trading as overall net income rose to $9.91 billion despite a stronger dollar, thanks to strong demand for the vaccine as well as its antiviral treatment Paxlovid.
Demand for the pill, which was used by President Joe Biden during his bout of COVID-19 infection, has picked up recently in the United States and other countries due to fresh outbreaks.
Pfizer has been banking on demand for vaccine boosters to drive up sales for the next few years.
The company and its partner BioNTech last month signed a $3.2 billion deal with the U.S. government for 105 million doses of their vaccine, which includes supply of retooled Omicron-adapted booster, pending regulatory clearance.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments